Upgrade to SI Premium - Free Trial

Gilead Sciences (GILD) Beats as Expected - Morgan Stanley

October 29, 2021 7:26 AM
Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $84.00 price target on Gilead Sciences (NASDAQ: GILD) after 3Q ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View

Next Articles